This information was published on 2025-06-22T00:04:17 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2528124 |
| (220) |
06 Mar 2025
|
| (300) |
US, 21 Jan 2025, 99014025
|
| (511) (510) |
Class 42
Drug discovery services; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence and machine learning for molecular docking; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for biomolecular structure prediction; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence in the field of drug design and development; research and development of new therapeutic targets for others; scientific and medical research; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for molecular docking; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for biomolecular structure prediction; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for automated machine learning in the field of drug design and development; advanced product research in the field of artificial intelligence (AI); research and development of pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; medical and scientific research services in the field of machine learning models for biomolecular structure prediction |
| (540) | NEURALPLEXER |
| (550) | Word |
| (730) |
Iambic Therapeutics, Inc.
|
| (750) |
Gilbert + Tobin Lawyers
|
Find out more about publications on the About page.